| scholarly article | Q13442814 |
| P2093 | author name string | Kyunga Kim | |
| Kyo Won Lee | |||
| Jae Berm Park | |||
| Wooseong Huh | |||
| Eun Suk Kang | |||
| Sooin Choi | |||
| Hye-Ryeon Jang | |||
| P2860 | cites work | C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study | Q90023517 |
| Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies | Q90584297 | ||
| Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 | ||
| Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation. | Q51479808 | ||
| Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes. | Q53826509 | ||
| C3d Assay in Correlation With Single Antigen Bead Assay for Human Leukocyte Antigen Antibodies | Q57489325 | ||
| Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients | Q59807564 | ||
| Pretransplant Donor-Specific HLA Class-I and -II Antibodies Are Associated With an Increased Risk for Kidney Graft Failure | Q60182181 | ||
| Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure | Q63866084 | ||
| C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney Transplantation | Q82659907 | ||
| Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection | Q84261290 | ||
| Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients | Q87006000 | ||
| Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients | Q87395286 | ||
| Analysis of predictive and preventive factors for de novo DSA in kidney transplant recipients | Q87646078 | ||
| Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies | Q87976540 | ||
| De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation | Q87987780 | ||
| Detection of Complement-binding Donor-specific Antibodies, Not IgG-antibody Strength Nor C4d Status, at Antibody-mediated Rejection Diagnosis Is an Independent Predictor of Kidney Graft Failure | Q88663306 | ||
| Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. | Q35027253 | ||
| Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection | Q35669313 | ||
| IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury | Q36417907 | ||
| The Banff classification revisited | Q38067050 | ||
| Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation | Q38108524 | ||
| The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients | Q38738885 | ||
| Relationship between Mean Fluorescence Intensity and C1q/C3d-fixing capacities of anti-HLA antibodies | Q38965721 | ||
| Donor-Specific Antibodies in Kidney Transplant Recipients | Q39265221 | ||
| The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation | Q41150961 | ||
| The impact of early de novo donor-specific antibodies on lung transplant outcomes: Is timing everything? | Q45041400 | ||
| Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 | ||
| Impact of Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on Kidney Allograft Outcome. | Q47130649 | ||
| Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies | Q47147931 | ||
| Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? | Q47880758 | ||
| Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. | Q48005087 | ||
| Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation | Q48255248 | ||
| Clinical utility of C3d binding donor-specific anti-human leukocyte antigen antibody detection by single antigen beads after kidney transplantation-a retrospective study. | Q48371099 | ||
| Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation. | Q50027507 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P577 | publication date | 2020-01-30 | |
| P1433 | published in | Journal of Clinical Medicine | Q27724774 |
| P1476 | title | C3d-Positive Preformed DSAs Tend to Persist and Result in a Higher Risk of AMR after Kidney Transplants | |
| P478 | volume | 9 |
Search more.